ALK Inhibitors in Non–Small Cell Lung Cancer: How Many Are Needed and How Should They Be Sequenced?

H&O Which patients with non–small cell lung cancer (NSCLC) are candidates for treatment with crizotinib? AS Crizotinib (Xalkori, Pfizer) is a multitargeted tyrosine kinase inhibitor […]

How I Treat Stage IV Non–Small Cell Lung Cancer in the Absence of Any Actionable Oncogenic Driver

Overview • Testing for several genetic alterations as well as programmed death ligand 1 (PD-L1) expression is paramount in the management of advanced, metastatic non–small cell […]

The Next Frontier in Non–Small Cell Lung Cancer: Synergizing Radiation Therapy and Immune Checkpoint Blockade

Abstract: Immune checkpoint blockade (ICB), which harnesses the body’s immune system to recognize and kill cancer cells, has transformed the management landscape for patients with […]

Does Plasma-Based Molecular Testing Have a Role in the Routine Care of Lung Cancer?

H&O What is the gold standard method for detecting genetic mutations in patients with lung cancer? HW The gold standard for detecting genetic mutations remains […]

Programmed Death Ligand 1 Testing: Is There One Best Test?

H&O Is programmed death ligand 1 (PD-L1) testing always done before prescribing a programmed death 1 (PD-1)/PD-L1 inhibitor in patients with non–small cell lung cancer […]

Optimal Treatment of Unresectable Stage III Non–Small Cell Lung Cancer

Clinical Advances in Hematology & Oncology Volume 14, Issue 11, November 2016 Jeffrey D. Bradley, MD S. Lee Kling Professor of Radiation Oncology Alvin J. Siteman […]

Moving Beyond Monotherapy in the Immunotherapeutic Arena: Prospects for Combination Therapies in Lung Cancer

Clinical Advances in Hematology & Oncology Volume 14, Issue 8, August 2016 Lung Cancer in Focus Scott J. Antonia, MD, PhD Chair of the Thoracic […]

HSP90 Inhibitors in Lung Cancer: Promise Still Unfulfilled

Abstract: Despite recent advances in the treatment of lung cancer, non–small cell lung cancer (NSCLC) remains the leading cause of cancer-related deaths in the United States […]

Angiogenesis Inhibition for the Treatment of Non–Small Cell Lung Cancer

Clinical Advances in Hematology & Oncology Volume 14, Issue 5, May 2016 Mark A. Socinski, MD Professor of Medicine and Cardiothoracic Surgery University of Pittsburgh Medical Center […]

Identifying and Addressing the Toxicity of Checkpoint Inhibitors in Lung Cancer

Clinical Advances in Hematology & Oncology March 2016, Volume 14, Issue 3 Julie R. Brahmer, MD Associate Professor of Medical Oncology Sidney Kimmel Comprehensive Cancer Center […]

Emerging Gene Mutation Targets in Lung Cancer

Clinical Advances in Hematology & Oncology December 2015, Volume 13, Issue 12 Bruce E. Johnson, MD Professor of Medicine Harvard Medical School Boston, Massachusetts H&O How […]

Selecting Patients for Immune Checkpoint Inhibition in Lung Cancer

Clinical Advances in Hematology & Oncology August 2015, Volume 13, Issue 8 Edward B. Garon, MD Associate Clinical Professor Director, Thoracic Oncology Program Jonsson Comprehensive […]